Yan Li, Jia-Yin Sun, Qian-Yun Guo, Hong-Ya Han, De-An Jia, Zhi-Ming Zhou, Zhi-Jian Wang, Ying-Xin Zhao, Yu-Jie Zhou, Shi-Wei Yang
{"title":"Impact of Variability in Blood Pressure and Heart Rate on Beta-Blocker Adherence","authors":"Yan Li, Jia-Yin Sun, Qian-Yun Guo, Hong-Ya Han, De-An Jia, Zhi-Ming Zhou, Zhi-Jian Wang, Ying-Xin Zhao, Yu-Jie Zhou, Shi-Wei Yang","doi":"10.1111/jch.70065","DOIUrl":null,"url":null,"abstract":"<p>Adherence to antihypertensive medications is essential for blood pressure (BP) control, influencing long-term outcomes in hypertensive patients. This study examines the association between visit-to-visit variability in BP and heart rate (HR) and its effect on adherence to beta-blocker therapy among outpatients. Conducted across 160 hospitals in China from January 1, 2011, to December 31, 2011, this study included 9225 hypertensive outpatients prescribed metoprolol succinate. BP and HR variability were assessed over three visits (baseline, 1-month, and 2-month follow-up) using standard deviation (SD) and mean-independent parameters. Nonadherence was defined as medication discontinuation or treatment regimen changes by the 2-month follow-up. Among the 9037 patients analyzed, the mean age was 58.85 years (±12.54), and 52.9% were male. Visit-to-visit variability in the rate–pressure product (RPP; SBP×HR) was a significant predictor of nonadherence, with an odds ratio (OR) of 1.26 (95% confidence interval [CI]: 1.04–1.53, <i>p</i> < 0.05) for the top-decile SD of RPP, independent of mean RPP. Variability in diastolic blood pressure (DBP) and pulse pressure (PP) were also associated with nonadherence, with ORs of 1.65 (95% CI: 1.35–2.00, <i>p</i> < 0.001) for DBP and 1.66 (95% CI: 1.39–1.99, <i>p</i> < 0.001) for PP, independent of their mean values. Patients with fluctuations in PP or HR had a higher risk of nonadherence compared to those with consistent reductions in these measures. Visit-to-visit variability in RPP, DBP, and PP is a significant predictor of nonadherence to beta-blockers, regardless of mean levels. Addressing this variability is critical for improving adherence to antihypertensive treatments and optimizing patient outcomes.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"27 5","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.70065","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.70065","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Adherence to antihypertensive medications is essential for blood pressure (BP) control, influencing long-term outcomes in hypertensive patients. This study examines the association between visit-to-visit variability in BP and heart rate (HR) and its effect on adherence to beta-blocker therapy among outpatients. Conducted across 160 hospitals in China from January 1, 2011, to December 31, 2011, this study included 9225 hypertensive outpatients prescribed metoprolol succinate. BP and HR variability were assessed over three visits (baseline, 1-month, and 2-month follow-up) using standard deviation (SD) and mean-independent parameters. Nonadherence was defined as medication discontinuation or treatment regimen changes by the 2-month follow-up. Among the 9037 patients analyzed, the mean age was 58.85 years (±12.54), and 52.9% were male. Visit-to-visit variability in the rate–pressure product (RPP; SBP×HR) was a significant predictor of nonadherence, with an odds ratio (OR) of 1.26 (95% confidence interval [CI]: 1.04–1.53, p < 0.05) for the top-decile SD of RPP, independent of mean RPP. Variability in diastolic blood pressure (DBP) and pulse pressure (PP) were also associated with nonadherence, with ORs of 1.65 (95% CI: 1.35–2.00, p < 0.001) for DBP and 1.66 (95% CI: 1.39–1.99, p < 0.001) for PP, independent of their mean values. Patients with fluctuations in PP or HR had a higher risk of nonadherence compared to those with consistent reductions in these measures. Visit-to-visit variability in RPP, DBP, and PP is a significant predictor of nonadherence to beta-blockers, regardless of mean levels. Addressing this variability is critical for improving adherence to antihypertensive treatments and optimizing patient outcomes.
坚持服用降压药物对于控制血压(BP)至关重要,影响高血压患者的长期预后。本研究探讨了门诊患者血压和心率(HR)的访间变异性之间的关系及其对β受体阻滞剂治疗依从性的影响。本研究于2011年1月1日至2011年12月31日在中国160家医院进行,纳入9225例门诊使用琥珀酸美托洛尔的高血压患者。通过三次随访(基线、1个月和2个月随访),使用标准差(SD)和均值独立参数评估血压和心率变异性。不依从性被定义为在2个月的随访中停止用药或改变治疗方案。9037例患者平均年龄58.85岁(±12.54岁),男性占52.9%。速率压力产品(RPP)的每次访问变异性;SBP×HR)是不依从的显著预测因子,比值比(OR)为1.26(95%可信区间[CI]: 1.04-1.53, p <;0.05)表示RPP的顶十分位SD,与平均RPP无关。舒张压(DBP)和脉压(PP)的变异性也与不依从相关,or为1.65 (95% CI: 1.35-2.00, p <;0.001)和1.66 (95% CI: 1.39-1.99, p <;0.001),与它们的平均值无关。与这些措施持续减少的患者相比,PP或HR波动的患者有更高的不依从风险。无论平均水平如何,RPP、DBP和PP的访间变异性是β受体阻滞剂不依从性的重要预测因子。解决这种变异性对于提高抗高血压治疗的依从性和优化患者预后至关重要。
期刊介绍:
The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.